Literature DB >> 8097674

Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.

J E Liebmann1, S M Hahn, J A Cook, C Lipschultz, J B Mitchell, D C Kaufman.   

Abstract

Taxol is a naturally occurring chemotherapeutic agent that is active against a variety of tumors. Taxol is believed to act by binding tightly to microtubules and preventing their disaggregation. Others have shown that depletion of cellular glutathione results in the disaggregation of microtubules, presumably by allowing the oxidation of some or all of the cysteine residues in tubulins. We studied the effect of glutathione (GSH) depletion by L-buthionine sulfoximine (L-BSO) on taxol cytotoxicity in two human tumor lines. After a 24-h incubation in 5 mM L-BSO, the breast adenocarcinoma line MCF-7 and the lung adenocarcinoma line A549 were exposed to varying concentrations of taxol for 24 h. GSH levels were undetectable in cells treated with L-BSO. At the highest concentrations of taxol (50 nM), control MCF-7 cells had 10% cell survival and control A549 cells had only 1% cell survival as assessed by clonogenic assay. Pretreatment with 5 mM L-BSO resulted in a 3-fold increase in survival of MCF-7 cells and a 10-fold increase in survival of A549 cells. Pretreatment with L-BSO had no effect on taxol uptake into A549 or MCF-7 cells, as assessed by measurement of binding of [3H]taxol to cells. Following exposure to 37 nM taxol for 24 h, both cell lines had over 80% of their population in G2/M and bromodeoxyuridine labeling showed that taxol markedly reduced the percentage of cells in S phase. L-BSO pretreatment had no effect on the cell cycle in either cell line in the absence of taxol. However, in cells treated with taxol, L-BSO increased the percentage of cells in S phase by 3-fold in both cell lines. We conclude that depletion of cellular GSH by L-BSO results in resistance to taxol in MCF-7 and A549 cells. Resistance to taxol mediated by GSH depletion is not due to alterations in cellular uptake of taxol by L-BSO. L-BSO increased the S-phase fraction of taxol-treated cells in both cell lines. These data suggest that GSH depletion interferes with cell cycle changes induced by taxol. The alteration in taxol-induced cell cycle effects may account for the resistance to taxol produced by L-BSO.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097674

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Mammalian Cells Exhibit a Range of Sensitivities to Silver Nanoparticles that are Partially Explicable by Variations in Antioxidant Defense and Metallothionein Expression.

Authors:  Haiyuan Zhang; Xiang Wang; Meiying Wang; Linjiang Li; Chong Hyun Chang; Zhaoxia Ji; Tian Xia; Andre E Nel
Journal:  Small       Date:  2015-04-30       Impact factor: 13.281

2.  Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics.

Authors:  W C Yen; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

Review 3.  Cytoprotection: concepts and challenges.

Authors:  F M Muggia
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

Review 4.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

5.  Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Authors:  Julie Scott; Robert T Dorr; Betty Samulitis; Terry H Landowski
Journal:  Cancer Chemother Pharmacol       Date:  2007-02-28       Impact factor: 3.333

6.  Consumption of redox energy by glutathione metabolism contributes to hypoxia/ reoxygenation-induced injury in astrocytes.

Authors:  Petr Makarov; Siegfried Kropf; Ingrid Wiswedel; Wolfgang Augustin; Lorenz Schild
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

7.  In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.

Authors:  Kaoru Okugawa; Hiroaki Kobayashi; Toshio Hirakawa; Takanori Sonoda; Tomonori Ogura; Hitoo Nakano
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-04       Impact factor: 4.553

8.  Effects of paclitaxel on permanent head and neck squamous cell carcinoma cell lines and identification of anti-apoptotic caspase 9b.

Authors:  Regina Maushagen; Stefan Reers; Ann-Christin Pfannerstill; Angelina Hahlbrock; Roland Stauber; Ramtin Rahmanzadeh; Dirk Rades; Ralph Pries; Barbara Wollenberg
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-01       Impact factor: 4.553

Review 9.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

10.  Chlorin e6 Conjugated Methoxy-Poly(Ethylene Glycol)-Poly(D,L-Lactide) Glutathione Sensitive Micelles for Photodynamic Therapy.

Authors:  Preeti Kumari; Milan Paul; Himanshu Bhatt; Sri Vishnu Kiran Rompicharla; Debolina Sarkar; Balaram Ghosh; Swati Biswas
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.